Related Experiment Video
Updated: Jul 4, 2026

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
Published on: January 9, 2026
[Impact of thrombophilic risk factors in patients with arterial thromboses]
1Praxis für Hämostaseologie und Transfusionsmedizin, Immermannstr. 65A, 40210 Düsseldorf. zotz.rainer@gmx.de
Thrombophilic risk factors of the vascular system are not as well defined as the classic risk factors of atherosclerosis or the thrombophilic risk factors of the venous system. Until now, the assessment is complicated by an inadequate differentiation between (a) proatherosclerotic and prothrombogenic effects (i. e. platelet receptor polymorphisms) and (b) reactive alterations of a haemostatic parameter (i. e. PAI-1, Fibrinogen) as an expression of an acute phase reaction and primary hereditary changes of those risk determinants. Actual data indicate for the majority of the potential risk factors only a mildly increased relative risk for an arterial ischaemic event and are often inconsistent. Anyhow, the impact of potential thrombophilic risk factors for the arterial vascular occlusion is not excluded. A possible reason is, that conventional case-control studies cannot identify risk factors of thrombogenicity in the arterial system unless they are also risk factors of atherosclerosis.
Thrombophilic risk factors of the vascular system are not as well defined as the classic risk factors of atherosclerosis or the thrombophilic risk factors of the venous system. Until now, the assessment is complicated by an inadequate differentiation between (a) proatherosclerotic and prothrombogenic effects (i. e. platelet receptor polymorphisms) and (b) reactive alterations of a haemostatic parameter (i. e. PAI-1, Fibrinogen) as an expression of an acute phase reaction and primary hereditary changes of those risk determinants. Actual data indicate for the majority of the potential risk factors only a mildly increased relative risk for an arterial ischaemic event and are often inconsistent. Anyhow, the impact of potential thrombophilic risk factors for the arterial vascular occlusion is not excluded. A possible reason is, that conventional case-control studies cannot identify risk factors of thrombogenicity in the arterial system unless they are also risk factors of atherosclerosis.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis I: Introduction
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...